Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Neoplasms × anlotinib × Clear all

Phase

Phase 2 5 Phase 2/3 1 Phase 1/2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 3 Stomach Neoplasms 1 Sarcoma 1 Neoplasms 1 Esophageal Squamous Cell Carcinoma 1 Differentiated Thyroid Cancer 1 Colorectal Neoplasms 1 Carcinoma, Medullary 1 Biliary Tract Neoplasms 1 Advanced Solid Tumor 1

Interventions

Trimethoprim, Sulfamethoxazole Drug Combination 3 Standard of Care 3 Oxaliplatin 3 Melatonin 3 Gemcitabine 3 Fluorouracil 3 Drug Therapy 3 Capecitabine 3 pertuzumab 2 gamma-Globulins 2 cobimetinib 2 Water 2 Vemurafenib 2 Trastuzumab 2 Sirolimus 2 Saline Solution 2 Methylphenidate 2 Lidocaine 2 Leucovorin 2 Immunoglobulins, Intravenous 2 Docetaxel 2 Dexmedetomidine 2 Ciprofloxacin 2 vedolizumab 1 valrubicin 1 trametinib 1 sotrovimab 1 sintilimab 1 relatlimab 1 racemetyrosine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02388919 2017-09-18

ALTER0303

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 2/3 Completed

Carcinoma, Non-Small-Cell Lung, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡